FDA Moves to Reclassify 12 Peptides in Major Regulatory Shift Driven by RFK Jr.

Executive Summary

The U.S. Food and Drug Administration announced on June 18, 2026 that it will convene an advisory committee in July 2026 to review whether seven peptide injections should be approved for compounding pharmacy production. Simultaneously, the agency will remove 12 peptides from the Category 2 bulks list — a restrictive classification reserved for unapproved, high-risk substances that cannot be compounded. The moves follow sustained pressure from Health and Human Services Secretary Robert F. Kennedy Jr. and the Make America Healthy Again (MAHA) movement, representing the most consequential shift in peptide regulation since the FDA began tightening compounding rules under the Biden administration.

Context / Background

The regulatory framework for compounded peptides sits at the intersection of drug safety law, pharmacy practice, and the growing consumer demand for “wellness” injectables. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare customized medications using bulk drug substances — but only if those substances appear on the FDA’s approved bulks list or have a USP/NF monograph.

Under President Biden, the FDA took an increasingly restrictive stance. Between 2022 and 2024, the agency added nearly 20 peptides — including BPC-157, Thymosin Alpha-1, and AOD-9604 — to Category 2, effectively banning their use in compounding. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted overwhelmingly that these substances “present significant safety risks” because most lack human clinical data. The peptide compounding industry, wellness influencers, and now the HHS Secretary himself have pushed back hard, arguing the restrictions limit patient access to promising therapies.

The Data / The Decision

Expert Insight

Anti-pattern: Treating this as a simple “pro-access vs. pro-safety” debate. Experienced regulatory professionals know the real strategic issue is regulatory pathway arbitrage. If peptides can reach patients through compounding pharmacies without an NDA or BLA, why would any company invest the $1–2 billion and 10–12 years required for formal drug approval? Dr. Peter Lurie’s warning — “I don’t see why one would take the path of a proper drug approval if there is now this less rigorous, alternative path to market” — isn’t hypothetical. The peptide therapeutics industry, which has attracted over $5 billion in venture funding since 2020, depends on a regulatory regime that rewards clinical development with market exclusivity.

The second-order effect most commentators miss: this reclassification doesn’t just affect wellness peptides like BPC-157. It creates a precedent for how the FDA handles the entire category of peptide drugs, including therapeutic peptides in active clinical development. A company with a Phase 2 peptide asset may now face competition from compounding pharmacies before it even reaches Phase 3 — a scenario that would fundamentally alter risk calculations for peptide biotech investors. CDMOs like Bachem and CordenPharma are watching this closely; expanded compounding could cannibalize the commercial manufacturing market they’re building capacity for.

Frequently Asked Questions

Which specific peptides is the FDA reviewing?

The FDA has not published the complete list of seven peptides to be reviewed at the July advisory committee meeting. Based on regulatory filings and industry reporting, the list is expected to include several peptides that were added to Category 2 during the Biden administration, including BPC-157, Thymosin Alpha-1, AOD-9604, and potentially GHK-Cu. The 12 peptides being removed from Category 2 include substances for which sufficient safety data or historical compounding precedent exists. The full docket will be published 30 days before the meeting.

How does this differ from the FDA’s separate action on GLP-1s?

These are two distinct regulatory actions moving in opposite directions. The peptide reclassification (this story) represents a loosening of restrictions — making it easier for compounding pharmacies to produce certain peptides. In contrast, the FDA is simultaneously moving to remove GLP-1 medications (semaglutide, tirzepatide) from the 503B bulks list, which would restrict large-scale compounding of these drugs by outsourcing facilities. The GLP-1 action protects the commercial market for approved drugs; the peptide reclassification opens the market for unapproved ones. The apparent contradiction reflects the complex political dynamics now shaping FDA policy.

What does this mean for the legitimate peptide therapeutics industry?

The impact is mixed and depends on which peptides are reclassified. For companies developing novel, patent-protected peptide drugs (GLP-1 multi-agonists, peptide-drug conjugates, macrocycles), the direct impact is minimal — these molecules are too complex for compounding pharmacies to replicate. However, for companies working on shorter, linear peptides that can be synthesized by compounding facilities, the reclassification introduces a new competitive threat. More broadly, the regulatory uncertainty may affect investor sentiment: if the FDA’s commitment to the NDA/BLA pathway for peptides is perceived as weakening, the premium that peptide biotechs command in M&A could compress.

Further Reading

• GLP-1 Peptide Therapeutics: The Complete 2026 Landscape
• Peptide CDMO Manufacturing Capacity: 2026 Outlook
• Peptide Regulatory Pathways: FDA vs EMA — A Comparative Analysis

Last reviewed: June 2026. Peptide Proof Editorial Team. Source: PBS News / Associated Press